[go: up one dir, main page]

HK1178910A1 - 用於治療癌症的人源化抗 抗體 - Google Patents

用於治療癌症的人源化抗 抗體

Info

Publication number
HK1178910A1
HK1178910A1 HK13105830.8A HK13105830A HK1178910A1 HK 1178910 A1 HK1178910 A1 HK 1178910A1 HK 13105830 A HK13105830 A HK 13105830A HK 1178910 A1 HK1178910 A1 HK 1178910A1
Authority
HK
Hong Kong
Prior art keywords
cxcr4
treatment
cancer
humanized anti
antibodies
Prior art date
Application number
HK13105830.8A
Other languages
English (en)
Inventor
．克林古爾漢默
．茹阿諾
．格勒尼耶-科薩內爾
．博格
Original Assignee
皮埃爾法布雷醫藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42556901&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1178910(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US12/749,891 external-priority patent/US8557964B2/en
Application filed by 皮埃爾法布雷醫藥公司 filed Critical 皮埃爾法布雷醫藥公司
Publication of HK1178910A1 publication Critical patent/HK1178910A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK13105830.8A 2010-03-30 2013-05-16 用於治療癌症的人源化抗 抗體 HK1178910A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10290167A EP2371863A1 (en) 2010-03-30 2010-03-30 Humanized anti CXCR4 antibodies for the treatment of cancer
US12/749,891 US8557964B2 (en) 2008-10-01 2010-03-30 Anti CXCR4 antibodies and their use for the treatment of cancer
PCT/EP2011/054945 WO2011121040A1 (en) 2010-03-30 2011-03-30 Humanized anti cxcr4 antibodies for the treatment of cancer

Publications (1)

Publication Number Publication Date
HK1178910A1 true HK1178910A1 (zh) 2013-09-19

Family

ID=42556901

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13105830.8A HK1178910A1 (zh) 2010-03-30 2013-05-16 用於治療癌症的人源化抗 抗體

Country Status (31)

Country Link
US (1) US9249223B2 (zh)
EP (2) EP2371863A1 (zh)
JP (1) JP5749330B2 (zh)
KR (1) KR101838310B1 (zh)
CN (1) CN102939306B (zh)
AR (1) AR080740A1 (zh)
AU (1) AU2011234458B2 (zh)
CA (1) CA2794407C (zh)
CL (1) CL2012002700A1 (zh)
CO (1) CO6571881A2 (zh)
CY (1) CY1115349T1 (zh)
DK (1) DK2552963T3 (zh)
ES (1) ES2469369T3 (zh)
HK (1) HK1178910A1 (zh)
HR (1) HRP20140502T1 (zh)
IL (1) IL222198A (zh)
MA (1) MA34175B1 (zh)
MX (1) MX2012011206A (zh)
NZ (1) NZ603182A (zh)
PH (1) PH12012501934A1 (zh)
PL (1) PL2552963T3 (zh)
PT (1) PT2552963E (zh)
RS (1) RS53405B (zh)
RU (1) RU2595394C2 (zh)
SG (1) SG184308A1 (zh)
SI (1) SI2552963T1 (zh)
TN (1) TN2012000466A1 (zh)
TW (1) TWI549689B (zh)
UA (1) UA106529C2 (zh)
WO (1) WO2011121040A1 (zh)
ZA (1) ZA201208015B (zh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2246364A1 (en) * 2009-04-29 2010-11-03 Pierre Fabre Médicament Anti CXCR4 antibodies for the treatment of HIV
AU2011322508A1 (en) * 2010-10-27 2013-05-02 Pierre Fabre Medicament Antibodies for the treatment of HIV
US20140120555A1 (en) * 2011-06-20 2014-05-01 Pierre Fabre Medicament Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
US11492383B2 (en) 2011-06-24 2022-11-08 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
TWI671317B (zh) 2013-08-02 2019-09-11 輝瑞大藥廠 抗ｃｘｃｒ４抗體及抗體-藥物結合物
SG10201914034WA (en) * 2016-01-13 2020-03-30 Regeneron Pharma Rodents having an engineered heavy chain diversity region
EP3471754A1 (en) 2016-06-20 2019-04-24 Kymab Limited Anti-pd-l1 antibodies
EP3774840A1 (en) 2018-03-27 2021-02-17 Bristol-Myers Squibb Company Real-time monitoring of protein concentration using ultraviolet signal
WO2020172658A1 (en) 2019-02-24 2020-08-27 Bristol-Myers Squibb Company Methods of isolating a protein
WO2020236792A1 (en) 2019-05-21 2020-11-26 Novartis Ag Cd19 binding molecules and uses thereof
EP3973274A1 (en) 2019-05-23 2022-03-30 Bristol-Myers Squibb Company Methods of monitoring cell culture media
KR20230080460A (ko) 2020-10-05 2023-06-07 브리스톨-마이어스 스큅 컴퍼니 단백질을 농축시키는 방법
EP4005923B1 (de) 2020-11-30 2023-08-30 Bucher Leichtbau AG Bordverpflegungsstation
KR20240156411A (ko) 2022-03-09 2024-10-29 브리스톨-마이어스 스큅 컴퍼니 치료 단백질의 일시적 발현

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4424200A (en) 1979-05-14 1984-01-03 Nuc Med Inc. Method for radiolabeling proteins with technetium-99m
US4479930A (en) 1982-07-26 1984-10-30 Trustees Of The University Of Massachusetts Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US7138496B2 (en) 2002-02-08 2006-11-21 Genetastix Corporation Human monoclonal antibodies against human CXCR4
US20050002939A1 (en) 2002-12-23 2005-01-06 Albert Zlotnik Tumor killing/tumor regression using CXCR4 antagonists
CA2536644A1 (en) * 2003-06-30 2005-02-03 Bio-Technology General (Israel) Ltd. Antibodies and uses thereof
ES2625798T3 (es) * 2006-10-02 2017-07-20 E. R. Squibb & Sons, L.L.C. Anticuerpos humanos que se unen a CXCR4 y usos de los mismos
FR2907341B1 (fr) * 2006-10-18 2012-08-17 Pf Medicament Utilisation d'un anticorps anti-cd151 pour le traitement du cancer
PL2119452T3 (pl) * 2006-12-26 2021-03-08 Centro De Inmunologia Molecular Kompozycja farmaceutyczna zawierająca przeciwciało monoklonalne anty-cd6 do zastosowania w diagnostyce i leczeniu reumatoidalnego zapalenia stawów
MX2010012435A (es) * 2008-05-14 2011-05-03 Lilly Co Eli Anticuerpos anti-cxcr4.
US9212226B2 (en) * 2008-05-16 2015-12-15 Ablynx N.V. Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same
EP2172485A1 (en) * 2008-10-01 2010-04-07 Pierre Fabre Medicament Novel anti CXCR4 antibodies and their use for the treatment of cancer
EP2246364A1 (en) * 2009-04-29 2010-11-03 Pierre Fabre Médicament Anti CXCR4 antibodies for the treatment of HIV

Also Published As

Publication number Publication date
US9249223B2 (en) 2016-02-02
MA34175B1 (fr) 2013-04-03
TN2012000466A1 (en) 2014-01-30
CY1115349T1 (el) 2017-01-04
CO6571881A2 (es) 2012-11-30
AR080740A1 (es) 2012-05-02
PL2552963T3 (pl) 2014-08-29
EP2552963A1 (en) 2013-02-06
EP2371863A1 (en) 2011-10-05
CL2012002700A1 (es) 2013-04-26
IL222198A (en) 2016-09-29
AU2011234458A1 (en) 2012-11-15
CA2794407A1 (en) 2011-10-06
NZ603182A (en) 2013-12-20
KR20130012132A (ko) 2013-02-01
IL222198A0 (en) 2012-12-31
PT2552963E (pt) 2014-06-03
KR101838310B1 (ko) 2018-03-13
CN102939306A (zh) 2013-02-20
RU2012145232A (ru) 2014-05-10
WO2011121040A1 (en) 2011-10-06
SG184308A1 (en) 2012-11-29
RU2595394C2 (ru) 2016-08-27
AU2011234458B2 (en) 2015-02-12
UA106529C2 (uk) 2014-09-10
TWI549689B (zh) 2016-09-21
EP2552963B1 (en) 2014-03-26
TW201136608A (en) 2011-11-01
CN102939306B (zh) 2015-07-22
HRP20140502T1 (hr) 2014-07-04
ES2469369T3 (es) 2014-06-18
MX2012011206A (es) 2013-02-11
DK2552963T3 (da) 2014-04-07
ZA201208015B (en) 2013-06-26
JP5749330B2 (ja) 2015-07-15
SI2552963T1 (sl) 2014-07-31
CA2794407C (en) 2019-02-19
RS53405B (en) 2014-10-31
US20130031647A1 (en) 2013-01-31
PH12012501934A1 (en) 2019-07-17
JP2013523106A (ja) 2013-06-17

Similar Documents

Publication Publication Date Title
HK1178910A1 (zh) 用於治療癌症的人源化抗 抗體
HK1254859A1 (zh) 治療乳腺癌的方法
IL228738A0 (en) Antibodies for cancer treatment
HRP20160714T1 (hr) Sredstva za induciranje apoptoze namijenjena liječenju raka i imunih i autoimunih bolesti
HK1199099A1 (zh) 用於治療和診斷癌症的方法和組合物
PL2482849T3 (pl) Skojarzona immunoterapia w leczeniu nowotworu
IL223070A (en) Cellular Death Causes for Cancer, Immunodeficiency, and Immune Failure
HUE047006T2 (hu) Anti-caprin-1 antitesteket tartalmazó gyógyászati kompozíció rák kezelésére és/vagy megelõzésére
HK1179614A1 (zh) 用於治療癌症和免疫以及自身免疫性疾病的細胞凋亡誘導劑
PL2550296T3 (pl) Przeciwciała monoklonalne w leczeniu nowotworów
HK1165813A1 (zh) 用於治療 的抗 抗體
PH12014500815A1 (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune
EP2651443A4 (en) ANTI-CCL25 AND ANTI-CCR9 ANTIBODIES FOR THE PREVENTION AND TREATMENT OF CANCER AND THE MIGRATION OF CANCER CELLS
HK1185874A1 (zh) 用於治療癌症的新的 -氨基- -羥基-苯甲酰胺
HRP20181212T1 (hr) Anti-alfa-v integrinsko protutijelo za liječenje raka prostate
IL223290A (en) Anti-1α-il antibodies for the treatment of arthritis

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190401